Abstract
INTRODUCTION. Many aspects of the drug safety profile, including rare and delayed adverse drug reactions (ADRs), are identified only in the post-marketing period when the drug is used in real-world clinical practice. However, the drawbacks inherent in spontaneous reporting and scientific literature monitoring (the main methods of post-marketing pharmacovigilance), such as incompleteness, fragmentation, variability in data quality, and the lack of standardized approaches to their analysis necessitate the systematization of information and the unification of approaches to data processing. AIM. To systematize information on the spontaneous reporting method and scientific literature monitoring, as well as on data processing approaches in post-marketing pharmacovigilance for risk management and ensuring drug safety. DISCUSSION . Spontaneous reporting is the basic passive method for post-marketing drug safety monitoring, with advantages including broad population coverage and the ability to detect a wide range of ADRs, including rare, delayed, and previously unknown ones. The effectiveness of the spontaneous reporting method can be enhanced through the development of educational programs for healthcare professionals and patients, the implementation of natural language processing (NLP) technologies to automate the extraction of structured information about ADRs from unstructured text sources, and integration with real-world data (RWD) to confirm signals and quantify risks. Scientific literature monitoring serves as a bridge between the passive collection of real-world data and evidence-based findings from controlled studies. An analysis of the EAEU Good Pharmacovigilance Practice Guidelines shows that when searching for information in the scientific literature, special aspects of the drug safety profile must be taken into account: effects on pregnancy outcomes, use in pediatrics, lack of efficacy, overdose, off-label use, and preclinical data. To standardize statistical methods for signal detection and the correct interpretation of signals (disproportionality analysis in spontaneous reporting databases), the READUS-PV guideline (2024) is recommended. CONCLUSIONS. The modern methodology of post-marketing pharmacovigilance is a dynamically evolving system. The presented systematization of approaches to spontaneous reporting and scientific literature monitoring, as well as the list of mandatory drug safety aspects, can serve as a practical tool for specialists in planning and conducting drug safety assessments.

This publication has 78 references indexed in Scilit: